Antibody binding and neutralization of live SARS-CoV-2 variants including BA.4/5 following booster vaccination of patients with B-cell malignancies

Non-Hodgkin lymphoma and chronic lymphocytic leukemia (NHL/CLL) patients elicit inadequate antibody responses after initial SARS-CoV-2 vaccination and remain at high risk of severe COVID-19 disease. We investigated IgG, IgA, and IgM responses after booster vaccination against recent SARS-CoV-2 varia...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research communications 2022-12, Vol.2 (12), p.1684-1692
Main Authors: Chang, Andres, Akhtar, Akil, Lai, Lilin, Orellana-Noia, Victor M, Linderman, Susanne L, McCook-Veal, Ashley A, Switchenko, Jeffrey M, Saini, Manpreet, Valanparambil, Rajesh M, Blum, Kristie A, Allen, Pamela B, Lechowicz, Mary Jo, Romancik, Jason T, Ayers, Amy, Leal, Alyssa, O'Leary, Colin B, Churnetski, Michael C, Baird, Katelin, Kives, Melissa, Wrammert, Jens, Nooka, Ajay K, Koff, Jean L, Dhodapkar, Madhav V, Suthar, Mehul S, Cohen, Jonathon B, Ahmed, Rafi
Format: Article
Language:English
Subjects:
Hematological Cancers
Immunology
Translational Research
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Non-Hodgkin lymphoma and chronic lymphocytic leukemia (NHL/CLL) patients elicit inadequate antibody responses after initial SARS-CoV-2 vaccination and remain at high risk of severe COVID-19 disease. We investigated IgG, IgA, and IgM responses after booster vaccination against recent SARS-CoV-2 variants including Omicron BA.5 in 67 patients. Patients had lower fold increase and total anti-spike binding titers after booster than healthy individuals. Antibody responses negatively correlated with recent anti-CD20 therapy and low B cell numbers. Antibodies generated after booster demonstrated similar binding properties against SARS-CoV-2 variants compared to those generated by healthy controls with lower binding against Omicron variants. Importantly, 43% of patients showed anti-Omicron BA.1 neutralizing antibodies after booster and all these patients also had anti-Omicron BA.5 neutralizing antibodies. NHL/CLL patients demonstrated inferior antibody responses after booster vaccination, particularly against Omicron variants. Prioritization of prophylactic and treatment agents and vaccination of patients and close contacts with updated vaccine formulations are essential.
ISSN:2767-9764
2767-9764
DOI:10.1158/2767-9764.CRC-22-0471